Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

The treatment of respiratory disease

A technology of use and medicine, applied in the direction of respiratory system diseases, cardiovascular system diseases, allergic diseases, etc.

Inactive Publication Date: 2007-04-18
SOSEI R&D LTD
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It does not address the duration of activity of glycopyrronium bromide and the suggested effective dose (200-1000 μg) is similar to the prior art mentioned above

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • The treatment of respiratory disease
  • The treatment of respiratory disease
  • The treatment of respiratory disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0060] A 75:25 mass ratio mixture of micronized glycopyrronium bromide and magnesium stearate (total mass approximately 1 g) was placed on top of 100 g of 2 mm diameter stainless steel balls in a ball mill. Grind volume was about 58.8ml. Add 5 ml of cyclohexane to wet the above mixture. The ball mill was sealed and secured in a Retsch S100 centrifuge. It was then centrifuged at 500 rpm for a total of 240 minutes. A small sample (approximately 5-10 mg) of the wet powder was removed from the ball mill every 60 minutes. The samples were vacuum dried in an oven at 37°C.

[0061] The resulting formulations were assayed. The method and results are documented below:

[0062] Primary Research in COPD - Research Criteria

[0063] Single-dose, double-blind, placebo-controlled ascending-dose study

[0064] 4 treatment days: randomly dosed in sequence of 60→120→240→480 μg with placebo

[0065] A total of 8 patients (1 withdrew midway)

[0066] COPD (FEV1; FVC1 <70%)

[0067] to ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

Glycopyrrate or an analogue thereof is useful for the treatment of bronchospasm or as a rescue medication.

Description

field of invention [0001] The present invention relates to the treatment of respiratory diseases. Background of the invention [0002] Glycopyrrolate has been known for many years to be a potent antimuscarinic agent. It has been used for several indications and delivered by many different routes. Recently, it has been used as an injection to reduce secretion during anesthesia and as an oral product for the treatment of gastric ulcers. One of the earliest indications of its use in airway diseases was in 1984, where it was shown to have a marked effect on bronchiectasis. Since then, many studies have been done to prove its potential utility. [0003] Schroeckenstein et al., J. Allergy Clin. Immunol., 1988;82(1):115-119, disclose the use of an aerosol formulation of glycopyrronium bromide for the treatment of asthma. A single metered dose of aerosol glycopyrronium bromide achieved bronchodilation over a 12-hour period. [0004] Leckie et al., Exp. Opin. Invest. Drugs, 2000...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61P11/00A61P11/08A61K31/40A61K31/465A61K31/00A61K31/352
CPCA61K31/00A61K31/40A61K31/352A61K31/465A61P11/00A61P11/06A61P11/08A61P37/08A61P43/00A61P9/14A61K2300/00
Inventor S·斯内普R·M·班尼斯特
Owner SOSEI R&D LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com